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INTRODUCTION
Carcinoma Breast is one of the commonest malignancies in women all over the 
world.
It causes about 20% cancer deaths among females. It is commonest malignancy of 
the female in India.i
The age standardized incidence rate of breast cancer in Indian population based 
registration varies  from 17-21.6 per  1,  00,000 population.  It  is  estimated  that  about 
75,000 new cases of breast cancer occurs in India every yearii
Carcinoma  breast  is  a  systemic  disease  even  on  initial  presentation.  The 
heterogeneous nature of the disease necessitates individualized treatment.  In spite  of 
major  advances  in  oncology  and  multimodality  approach  towards  treatment  of 
Carcinoma Breast there is not much decrease in mortality. This study is undertaken to 
find out the various prognostic and risk factors for Carcinoma Breast in Patients who 
attended  Kilpauk  Medical  College  Hospital  Department  of  Surgery  &  Surgical 
Oncology. 
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AIMS AND OBJECTIVES 
1. To study the incidence, geographic pattern and other epidemiological factors of 
Carcinoma Breast.
2. To study the role of possible environmental factors in the genesis of Carcinoma 
Breast in our region.
3. To study the various prognostic factors of Carcinoma Breast.
4. To study the histopathological types of Carcinoma Breast.
REVIEW OF LITERATURE
Embryologyv
Breast is a modified sweat glands embryologicaly derived from down growth of 
ectoderm into underlying mesenchyme
Anatomyvi
It  is  extended from the 2nd rib  to  6th rib.  Blood supply lateral  thoracic  artery, 
perforating cutaneous branches of internal mammary artery from 2nd, 3rd, 4th spaces, 
lateral branches of 2nd, and 3rd, 4th intercostal arteries
Nerve supply 
Secreting  tissue  supplied  by  sympathetic  nerves  which  reach  via  2nd,  to  6th 
intercostal nerve. Overlying skin is supplied by anterior and lateral branches of 4th, 5th, 
6th intercostal nerve.
vii
Physiology
Appreciation  of  stages  of  breast  development  is  necessary  to  understand  the 
benign and malignant condition of breast tissue.
During adolescence, breast is composed of lobular stoma scattered ducts lined by 
epithelium. During puberty increased deposition of fat and formation of new ducts by 
branching,  elongation  and first  appearance  of  lobular  units.  The  progress  of  growth 
entails cell division and is under the control of estrogen, progesterone, adrenal hormone, 
pituitary hormone, thyrotrophic hormone, and insulin.
During phases  of  menstrual  cycle  or  in  response  to  exogenous  hormones,  the 
breast  epithelium and lobular  stroma under go cyclic stimulation.  It  appears that the 
dominant process is hypertrophy and alteration in morphology rather than hyperplasia.
In late  luteal  phase there is  accumulation of  fluid and interlobular  edema that 
appears to correspond to breast engorgement.
It  is  only  with  the  onset  of  pregnancy  that  the  breast  assumes  its  complete 
morphologic maturation and functional activity. By the end of pregnancy the breast is 
composed entirely of glands separated relatively scanty amount of stroma. The secretary 
glands are lined by cuboidal cells, in third trimester secretary vacuoles of lipid material 
are found with in the cell. 
Following lactation the glands once again regress and atrophy, ducts shrink .at 
menopause  ducts  and  glands  further  atrophied  with  more  shrinkage  of  inter  and 
intralobular stroma. The gland almost totally disappears leaving only the ducts.viii
Risk factorsix
They are genetic, endocrine and environmental.
Age 
Cumulative risk between 20-40 years is 0.5% 
From 20 to 30 years there is a steep rise in age specific cancer 
Family history
If the first degree relative has Carcinoma Breast, relative risk is 1.7% -2.5%. If the 
second degree relative had Carcinoma Breast, risk is 1.5 %.Direct genetic factor risk is 
about 5%.
Parity 
In single para and nullipara relative risk is 1.4% compared to multipara
Geneticx
High incidence of Carcinoma Breast is seen in women with inherited mutation of 
two breast cancer gene BRCA1, BRCA2. Risk is 7%
It is estimated that approximately 5%of all women with Carcinoma Breast may 
have  the  recently  identified  germ  line  mutation  in  a  gene  BRCA1,  located  in 
chromosome 17q21. Their relatives if carriers of BRCA 1 mutation may have 85%life 
time for breast cancer with 50% of Carcinoma Breast occurring before 50 years of age. 
Menarche
Before 12 years relative risk is 2.3 %. Duration of the menstrual life is important 
factor for breast cancer. Artificial menopause by oopherectomy or irradiation reduces 
the risk.
Body weightxi
Women under the age of  50 years there is  little  correlation between the body 
weight and cancer.
Diet 
Alcohol increase the risk 1.5%. High fat in diet increases the risk.
Oral contraceptives
Risk is 0.4% and up to 5 years risk is 1.2%. 
Ionizing radiation 
Thymus radiation, nuclear war, professional exposure increased the risk apparent 
after a latent period of 10 to 15 years, if the women were exposed before the age of 35.
Benign breast lesionxii
Fibrocystic disease with atypia is more prone for Carcinoma Breast.
Pathologyxiii
With increasing use of screening mammography, Non invasive cancers are more 
frequently diagnosed and now constitute 15-20% of all breast cancers. There are many 
methods of pathologically classifying Carcinoma Breast. Most are based on whether the 
tumor is invasive or noninvasive and whether it is derived from the duct system or the 
lobule. Most tumors arise from the ductules. 
Invasive ductal carcinoma
This is the most common type of breast carcinoma. It is a stony hard tumor. Gritty 
on  transection  show  tumor  retraction  below  cut  margins.  Microscopically  primitive 
glandular pattern is seen. Metastasis to axillary lymph nodes is common. Prognosis is 
poor.
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PAPILLARY CARCINOMA
This is slow growing bulky circumscribed tumor occurring characteristically in 
post menopausal woman. Microscopically a vascular anaplastic growth extends along 
the  thickened  ductal  wall  into  the  surrounding  tissue.  The  prognosis  is  better  than 
invasive ductal carcinoma.
MEDULLARY CARCINOMA
Solid syncytium like sheets of large cells with vesicular often pleomorphic nuclei. 
There is moderate to marked lymphocytic infiltration. 10 year survival rate is 90%.
COLLOIDAL MUCINOUS
Prognosis is good. Lymph nodal metastasis is infrequent.
LOBULAR CARCINOMA
Most  common cause of  bilateral  carcinoma is lobular  carcinoma. Prognosis  is 
poor. Multicentric in origin.
Spread of cancer breastxv
Direct  spread  into  the  parenchyma  occurs  in  a  characteristic  satellite  pattern. 
Spread  along  the  lymphatics  to  the  regional  nodes.  Spread  along  the  ducts  –field 
cancerization. blood spread to lungs, bone, liver, adrenals and ovary.
Clinical feature
Breast lump, nipple discharge, pain, loss of weight, axillary node, breast ulcer, 
nipple  retraction and others  are  common clinical  features.  While  any portion  of  the 
breast,  including  the  axillary  tail,  may  be  involved,  breast  cancer  commences  most 
frequently in the upper, outer quadrant. Most breast cancers will present as a hard lump, 
which may be associated with in drawing of the nipple. As the disease advances locally 
there may be skin involvement with peau d’orange or frank ulceration and fixation to the 
chest wall. This is described as cancer-encuirasse. About 5 percent of Carcinoma Breast 
in the UK will present with either locally advanced disease or symptoms of metastatic 
disease. This figure is nearer 20 per cent in the developing world. These patients must 
then  undergo  a  staging  evaluation  so  that  the  full  extent  of  their  disease  can  be 
ascertained. This will include a careful clinical examination, chest X-ray, serum alkaline 
phosphatase and gamma glutamine transaminase (GGT), with liver ultrasound if these 
are  abnormal,  and  an  isotope  bone  scan  .This  is  important  for  both  prognosis  and 
treatment  — a patient  with widespread visceral  metastases  may obtain an increased 
length and quality of survival from systemic hormone or chemotherapy, but she is not 
likely to benefit from surgery as she will die from her metastases before local disease 
becomes  a  problem.  In  contrast,  patients  with  relatively  small  (less  than  5  cm  in 
diameter) tumours confined to the breast and ipsilateral lymph nodes rarely need staging 
beyond a good clinical examination as the pick-up rate for distant metastases is so low
Investigationsxvi
Non invasive
1. MAMMOGRAM
2. ULTRA SONOGRAM
3. CT
4. MRI
Invasive
1. FINE NEEDLE ASPIRATION CYTOLOGY
2. TRUCUT BIOPSY
3. INCISION BIOPSY
4. EXCISION BIOPSY
Others 
1. SERUM ESTROGEN ESTIMATION
2. SERUM CHOLESTEROL ESTIMATION
3. SEROLOGICAL MARKERS
a. estrogen receptor immunocyte chemical assay
b. C erb B2 (HER 2 /neu)
c. Ps 2
Breast screeningxvii
National breast cancer screening in UK is well established. The results of chamber 
lien etal 1993 are the overall acceptance rate was 71%. The breast cancer detection rate 
was 6.2 per thousand women. 95% of the programme achieved a recall rate of less than 
10 % .these results are extremely satisfactory. The largest reduction of mortality rate 
was observed in  50-60 years.   Among women age 40-49 there  was no reduction in 
mortality.  Un doubtfully  screening tests  detects  tumor in earlier  biological  stage but 
false positivity causes anxiety and necessitate further diagnostic procedures. 
 Prognosis of breast cancerxviii
Patient related 
Tumor related 
Treatment related
Patient related
More frequent of local recurrence in younger patients.
TUMOR RELATED
Histological grade 
1. Cytoarchitectural type. 
There is no significant prognostic difference between ordinary invasive ductal and 
invasive lobular carcinoma. Morphologic variants of invasive ductal carcinoma 
with a  more favorable  prognosis  are  tubular  carcinoma,  cribriform carcinoma, 
medullary carcinoma (when strictly defined), pure mucinous carcinoma, papillary 
carcinoma,  adenoid  cystic  carcinoma,  and  juvenile  (secretory)  carcinoma.  A 
variant of lobular (and sometimes ductal) carcinoma associated with an extremely 
bad prognosis is signet ring carcinoma. The prognosis of inflammatory carcinoma 
is also particularly ominous. 
2. Microscopic grade. 
The two most widely used systems over the years for the microscopic grading of 
breast carcinoma have been those of Bloom and Richardson and Black, the first 
based mainly on architectural features (extent of tubule formation) and the second 
on the degree of nuclear atypia. Since both architecture and cytology have been 
found to correlate with prognosis,  the sensible proposal  has been made to use 
them in conjunction.
Elston  has  been  the  most  vocal  champion  of  this  approach,  which  is  usually 
referred to as the Nottingham modification of the Bloom-Richardson system and 
which also  incorporates  the  evaluation of  mitotic  activity.  In  this  scheme,  the 
grade  is  obtained  by  adding  up  the  scores  for  tubule  formation,  nuclear 
pleomorphism, and mitotic count, each of which is given 1, 2, or 3 points. This 
results in a total score of 3 to 9 points, which is translated into the final grade by 
the following formula:
3 to 5 points    - Grade I;
6 to 7 points    -Grade II; 
8 to 9 points    -Grade III. 
3. Type of margins.
Tumors  with  "pushing"  margins  have  a  better  prognosis  than  tumors  with 
infiltrating margins.  This applies not only to medullary carcinoma, but  also to 
other types of well-circumscribed neoplasm. 
4. Tumor necrosis. 
Tumor  necrosis  is  associated  with  an  increased  incidence  of  lymph  node 
metastases and decreased survival rates, but this feature is usually associated with 
tumors of high histologic grade.
5. Stromal reaction.
Surprisingly,  it  has  been  found  that  tumors  with  an  absence  of  inflammatory 
reaction at the periphery have a lesser degree of nodal metastases and presumably 
a better prognosis. Obviously, these considerations do not apply to the specific 
case of medullary carcinoma.
6. Microvessel density. 
The  very  interesting  observation  has  been  recently  made  that  invasive  breast 
carcinomas having a prominent vascular  component in the surrounding stroma 
behave  in  a  more  aggressive  fashion than the  others.  It  should be  added that 
microvessel density is a phenomenon independent from intratumoral endothelial 
cell proliferation, and that an increase in microvessel density has also been noted 
in intraductal carcinoma, particularly of the comedo type.
7. Elastosis.
It has been claimed that breast carcinomas with no associated elastosis have a 
lower rate of response to endocrine therapy than those with gross elastosis.  In 
terms of survival rate, no convincing differences have been found between tumors 
with and without elastosis. 
8. CEA staining pattern.
This immunohistochemical feature has not been found to relate to prognosis. 
9. Vimentin staining pattern.
The  claim  has  been  made  that  Vimentin  expression  is  associated  with  poor 
prognosis in node-negative ductal carcinomas
10. Cathepsin D. 
Despite  original  claims  to  the  contrary,  assays  for  neither  cathepsin  D 
immunoreactivity in the tumor nor serum levels of this enzyme have proved to 
have independent prognostic value. 
11. C-erbB-2 (neu/HER-2) oncogene.
As  already  stated,  amplification  of  this  oncogene  (which  encodes  a 
transmembrane glycoprotein with tyrosine kinase activity known as p185) is seen 
in  almost  all  cases  of  comedo-type  intraductal  carcinoma,  in  10% to  40% of 
invasive ductal carcinomas and in only a few cases of invasive lobular carcinoma. 
12. p53 and nm23. 
Accumulation of  p53 protein have been said to correlate  with reduced patient 
survival. 
13. Bcl-2.
A relationship between Bcl-2 protein expression and long-term survival in breast 
carcinoma has been shown. Bcl-2 is also correlated with estrogen receptor status. 
14. Skin invasion. 
Breast  carcinomas  in  which  invasion  of  the  overlying  skin  has  occurred  are 
associated with a decreased survival rate. Invasion of dermal lymph vessels as a 
determinant of the "inflammatory carcinoma" picture is a particularly ominous 
prognostic sign.
15. Nipple inversion.
Involvement of the nipple by carcinoma is associated with a higher incidence of 
axillary metastases. 
16. Lymphatic tumor emboli. 
The presence of tumor emboli in lymphatic vessels within the breast is associated 
with an increased risk of tumor recurrence.  Blood vessel  emboli.  This finding 
shows a high correlation with tumor size,  histologic grade, tumor type, lymph 
node status, development of distant metastases, and poor prognosis. 
17. Paget's disease.
The presence or absence of Paget's disease in invasive ductal carcinoma is of no 
prognostic relevance per se.
18. Estrogen receptors.
Several  authors  have  concluded  that  patients  with  estrogen  receptor  positive 
tumors— whether determined biochemically or immunohistochemically—have a 
longer disease-free survival than the others. However, the differences in long-term 
prognosis are minimal and perhaps not statistically significant. 
19. DNA ploidy.
20.Cell proliferation.
Determination  of  S-phase  fraction  by  flow  cytometry  has  emerged  as  a  very 
important  prognostic  determinator.  As  such,  it  has  been  incorporated  into  the 
combined grading scheme espoused by Elston 
21. Axillary lymph node metastases.
This is one of the most important prognostic parameters. Not only is there a sharp 
difference in survival rates between patients with positive and negative nodes, but 
the  survival  rate  also  depends  on  the  level  of  axillary  node  involved  (low, 
medium, or high), the absolute number (fewer than four versus four or more), the 
amount of metastatic tumor, the presence or absence of extra nodal spread, and 
the  presence  or  absence  of  tumor  cells  in  the  efferent  vessels.  Interestingly, 
patients in whom the initial lymph node sections are negative but who are found 
to have micro metastases on serial sections have the same prognosis as patients in 
whom no tumor is found. For prognostic purposes, the best grouping seems to be 
the  following:  negative  nodes,  one  to  three  positive  nodes,  and  four  or  more 
positive nodes.
22. Pattern of lymph node reaction.
It  has  been  suggested  that  the  microscopic  appearance  of  the  regional  node 
(lymphoid response and/or sinus histiocytosis) is an indication of the type of host 
response  to  the  tumor  and  that  it  relates  to  prognosis.  The  issue  remains 
controversial; if there is indeed a correlation, it does not seem to be a statistically 
significant one. 
23. Internal mammary lymph node metastases. 
Survival in patients with involvement of this lymph node group is lower than in 
those  without  such  involvement,  especially  if  only  patients  with  one  to  three 
positive axillary nodes are evaluated. 
24. Local recurrence. 
This is a sign of ominous prognosis. In one series of sixty patients with ipsilateral 
chest wall recurrence and no detectable distant metastases, all patients eventually 
died of metastatic breast carcinoma.
TREATMENT RELATED
This is too complex and multifactorial an issue to be properly addressed here. 
Suffice to say that all available evidence suggests that the outcome in breast carcinoma 
depends  more  on  the  nature  of  the  individual  tumor  than  on  the  type  of  therapy 
performed. There is certainly a striking similarity in survival rates from different centers 
employing widely disparate therapeutic approaches. A complicating factor in evaluating 
therapeutic results is the marked individual variations in the natural life history of the 
disease, which renders imperative use of carefully randomized studies. Most of these 
studies have shown no significant differences in survival among the various groups.
Treatmentxix
The therapy of breast  carcinoma includes surgery,  radiation therapy, hormonal 
therapy,  and  chemotherapy  (the  latter  sometimes  combined  with  bone  marrow 
transplantation), depending on the type and extent of the disease. 
Surgical  therapy,  traditionally  synonymous  with  Halsted's  radical  mastectomy, 
now comprises  a  wide  variety  of  newer  options,  which  include  partial  mastectomy 
(lumpectomy  or  segmentectomy),  total  (simple)  mastectomy,  and  modified  radical 
mastectomy.
Radiation therapy has been employed as a postoperative adjunct (especially in 
connection with the more limited operations), sometimes as the primary treatment, and 
for the control of locally recurrent disease.
When conservative surgery is employed, microscopic evaluation of the surgical 
margins  becomes  necessary.  Several  studies  have  shown  that  patients  with  positive 
margins are more likely to develop local recurrence as well as distant failure. Surgical 
margins are more difficult to evaluate for intraductal tumors, and their very utility in this 
circumstance has been questioned.
Breast  implants  used  for  reconstructive  purposes  usually  develop  a  fibrous 
capsule  around them .The  inside  surface  of  this  capsule  has  a  tendency  to  undergo 
synovial metaplasia; a process that has also been referred to as pseudoepithelization and 
that  is  microscopically  very  similar  to  "detritic  synovitis.  Rarely,  the  capsule  is 
surrounded by benign squamous epithelium. 
Systemic  therapy  is  used  for  the  treatment  of  generalized  disease.  Hormonal 
therapy, which has traditionally included the options of castration, adrenalectomy, and 
hypophysectomy, is now largely dependent on anti-estrogen drugs, of which tamoxifen 
has emerged as the most important. 
Chemotherapy  has  had  a  significant  impact  on  the  survival  of  patients  with 
metastatic  breast  carcinoma,  the best  results  having been obtained with combination 
regimens.  In  highly  selected patients,  this  has  been combined with autologous bone 
marrow transplantation; it remains to be seen whether the survival benefit justifies the 
considerably high cost of the procedure.
In  addition,  chemotherapy  is  currently  used  as  an  adjunct  following  local 
treatment with curative intent in patients with positive axillary nodes. The decision as to 
whether  to  give  chemotherapy  or  hormonal  therapy  to  node-negative  patients  is  a 
difficult  one and is  dependent  upon a  variety  of  clinical  and pathologic  parameters. 
Chemotherapy has also been used sequentially combined with conservative surgery and 
radiation in patients with localized large (>=3 cm) tumors in order to avoid mastectomy.
MATERIALS AND METHODS
Fifty cases of Carcinoma Breast admitted in various surgical units and surgical 
Oncology Unit in Kilpauk Medical College Hospital, Chennai over a period of 3 years 
from 2003- 2006 were taken up for this study.
A complete clinical evaluation of the cases including history, physical examination and 
necessary investigations were done to confirm the diagnosis, stage of disease and definitive treatment.
Investigations done were FNAC, TRUCUT biopsy, excision biopsy, plain X ray 
chest, and ultrasound abdomen in all cases. 
For all stages of Carcinoma Breast, surgery is done for loco regional control of the disease in 
our institution. Modified radical mastectomy, simple mastectomy, hormone therapy radiotherapy, and 
chemotherapy were given. CMF (Cyclophophamide, Methotraxate, and 5-Flurouracil) or CAF 
(Cyclophophamide, Adriamicin, and 5-Flurouracil) regimen is used for chemotherapy. Tamoxifen and 
bilateral oopherectomy were used for hormone therapy.
Patients had regular follow up at regular intervals to find out morbidity, disease free survival, 
local recurrence, systemic metastasis and overall survival. X ray chest, ultrasound abdomen, liver 
function test, complete hemogram were done for every 6 months, skeletal survey in selected cases were 
done.
RESULTS OF THE STUDY
Fifty cases of cancer breast admitted in various surgical units in Kilpauk Medical 
College Hospital were studied during the period of 2003 to 2006.
 
Age
In our series of study the highest incidence of breast cancer has occurred in the 
age group between 40-50 years
The youngest patient is 24 years old female
Menstrual status
Average age of menarche is 14 years.
Earliest being 12 years of age, and delayed menstruation up to                     17 years of age.
Parity
Unmarried 2
Nullipara 4 
Para one 8
Para2-3 21
Para 3 – 5 10
More than 5 5
Lactational status
 Average duration of Lactational time is more than one year in 42% cases.
4 cases were Nullipara and two patients were unmarried.
Duration of lactation No of cases
< 3 months 2
3-6 months 5
7-9 months 12
10-12 months 4
More than 12 months 21
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No 
of 
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Parity
Age at first child birth
 The entire patient had their first child birth before 28 years. None of the mother 
had first child after 28 years. Nullipara 4 cases. Unmarried 2 cases.
Age in years No of cases
<16 1
16 – 19 9
20 – 23 18
24 – 27 15
> 27 1
Socio economic status
Low Upper
48 2
Religion
Hindu 39
Christian 7
Muslims 4
RELIGION
Hindu
Christian 
Muslim
SOCIO ECONOMIC STATUS
Low
Upper 
Geographic distribution
The  cases  reported  were  from North  Tamil  Nadu  and  Migrants  from Andhra 
Pradesh to Tamil Nadu.
 
Clinical feature
All cases were presented with lump breast. In 15 patients pain was associated with 
lump breast. Discharge from nipple was present in 4 cases only.
Duration of lump No of cases
< 3 months 12
4-5 months 12
6-7 moths 11
8-9 months 4
10-11 months 6
> one year 5
Discharge from the nipple
 
Less than one week         1
Less than 15 days 2
Less than one month 1
Site
Left breast is affected in 54% of cases in my series. Upper outer quadrant is more 
commonly involved (44%).
Upper outer 22
Upper inner 6
Lower outer 9
Lower inner 6
Central 5
Diffuse 2
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Comparision of Quadrant affected
TN
M staging
Staging No of cases Staging No of cases
T1 N0 M0 0 T3 N1 M0 16
T1 N1 MO 0 T3 N2 M0 2
T2 N0 M0 4 T4 N1 M0 4
T2 N1 M0 11 T4 N2 M0 1
T2 N2 M0 2 T4 N3 M0     1
T2 N2 M1 0 T4 N2 M1 1
T3 N0 M0 8
 
Staging
Stage No of cases
Stage I 0
Stage II A 4
Stage II B 20
Bailey
Devita
Study
Stage III A 19
Stage III B 5
Stage IV 1
Investigation
Fine needle aspiration cytology
Positive in 45 cases
Inconclusive in 5 cases
Trucut biopsy
Positive in 4 cases 
Negative in 1 case
Histopathological examination
Invasive ductal carcinoma NOS   48 cases
Lobular carcinoma                         1 case
Paget’s     1 case
Nodal status
Axillary node was clinically positive in 37 cases. Biopsy proved in 25 cases. 
Supraclavicular node was clinically positive in 1 case. Biopsy positive in 1 case
Opposite axilla positive in 1 case
Treatment 
Modalities of treatment
1. Surgery
Type of surgery No of cases
Patey’s modified radical mastectomy 
(post menopausal women) 35
Patey’s modified radical mastectomy
with bilateral oopherectomy(pre 
menopausal women)
09
Palliative total mastectomy 4
Lumpectomy 2
2. Chemotherapy
All the cases except 5 cases treated with CAF regime 6 cycles Cyclophosphamide, 
doxorubicin, and fluorouracil (CAF).
CYCLOPHOSPHAMIDE
40 to 50 mg per kg of body weight in divided doses over a period of two to five 
days, or 10 to 15 mg per kg of body weight every seven to ten days, or 3 to 5 mg per kg 
of body weight two times a week, or 1.5 to 3 mg per kg of body weight a day.
ADRIAMYCINE
Intravenous, 60 to 75 mg per square meter of body surface area, repeated every 
twenty-one days
5-FLUROURACIL
300 to 500 mg per square meter of body surface repeated monthly.
3. Endocrine manipulation
Tamoxifen was given to post menopausal case. (Tamoxifen 10 mg twice a day for 
5 years)
Morbidity of surgery
Wound infection 3 cases
Flap necrosis 5 cases
Lympodema 8 cases
Lymph collection 15 cases 
Numbness 12 cases
Frozen shoulder 2 cases
Discussion
This is a study of 50 cases of Carcinoma Breast during the period of 2003- 2006.
 
Causes  of  Carcinoma  Breast are  unknown.  However  epidemiological  data 
indicates well defined factors that indicate the liability to breast cancer. Such factors are 
genetic, endocrine and environmental.
Agexx
Carcinoma  Breast incidence  is  increasing  with  age.  Carcinoma  Breast is 
occasionally seen in late teens but there after there is a rapid age specific rise up to 40 
years. Then the rate is increases slowly although overall breast cancer rate continues 
until old age. The cumulative risk for developing breast cancer between ages 20-40 is 
0.5% .where as between 50-70 is 5 %.this accounts for the fact that majority of the 
breast cancer patients are over 50 years of age.
In my study the incidence of carcinoma breast in the age group of 30-40. is 28%, 
between 40-50 years is 38% incidence above 50 years is 22%.
As comparable to western series there is a steady increase in incidence after 30 
years.
 The  development  of  second  breast  cancer  may  be  a  clinical  manifestation  of 
multifocal origin of breast cancer or may be an entirely new occurrence. There appears 
to be an overall rise 0.75-1% per year. Thus the relative risk of developing the second 
non synchronous primary, after 20 years of initial diagnosis of the disease is 1.5%. 
Menarche xxi
Age of menarche and establishment of regular ovarian cycle seems to be strongly 
associated with breast cancer risk.  Woman whose menarche occurs before the age of 12 
has relative risk of 2.3 %. When the menarche is associated with delay in establishment 
of regular ovulatory cycles, there is 20% decrease in the breast cancer incidence and it’s 
thought to have an additional protective effect. 
In  my  study,  only  2%  of  the  patients  menstruated  at  the  age  of  12. 
30%menstruated at 13 years. 30% menstruated at 14 years. 28%menstruated at 15 years. 
6% menstruated at the age of 16 years and 4% menstruated at the age of 17 years. Age at 
menarche has little significance and less protective in this series of study.
Family historyxxii
Female relatives of the breast cancer may have increased risk of disease. The risk 
is greatest in patients with first degree relatives, especially when the patient is under the 
age of 50 at the time of diagnosis. 
If the first degree relative has  Carcinoma Breast, relative risk is 1.7 -2.5. If the 
second degree relative had Carcinoma Breast, risk is 1.5 %. Direct genetic factor risk is 
about 5%.
The BRCAI gene has been cloned and is located on the long arm of chromosome 
17 (17q).  The gene frequency in the population is  approximately 0.0006.  BRCA2  is 
located  on  chromosome  13q.  Women  who are  thought  to  be  gene  carriers  may  be 
offered breast screening (and ovarian screening in the case of BRCA1, which is known 
to impart a 50 per cent lifetime risk of ovarian cancer), usually as part of a research 
programme, or may be offered generic counselling and mutation analysis. Those who 
prove  to  be  ‘gene  positive’  have  an  80  per  cent  risk  of  developing  breast  cancer, 
predominantly  whilst  premenopausal.  Many  will  opt  for  prophylactic  mastectomy, 
although this does not completely eliminate the risk. 
Radiationxxiii 
An increased risk of the breast  cancer  has been found in survivors of  nuclear 
exposure,  women  treated  for  postpartum  mastitis  by  irradiation  and  professionals, 
patients exposed to multiple radiographs
In my study there is no predisposing factor like irradiation.
Body weightxxiv
There is little correlation between risk of breast cancer and body weight. In my 
study the minor  controversial  risk factors  like alcohol,  diet,  oral  contraceptives,  and 
hormonal replacement therapy are not found. Though 8% showed diabetes mellitus, in 
which there may be a disturbance in cholesterol metabolism and level of estrogen.
Benign breast lesion
Benign breast lesions except multiple papillomatosis are not usually recognized as 
a  major  risk  factor.  There  are  no  such  predisposing  factors  in  my  study,  except 
premenstrual cyclical mastalgia in 6 patients.   
Age at first child birthxxv
In contrast to western study the patients with first child birth before the age of 19 
were 38%. In 36% of the patients the first childbirth was between 20-23 years
         About 74% of our patients had their first child birth before 23 years. The protective 
influence of early age at first child birth is less significant. In this study. 
Parityxxvi
Multi  parity  is  not  protective against  breast  cancer.  Nulliparity has the risk of 
1.4% compared to parous women. However this protective effect of parity is totally due 
to age at first child birth. In those, whose first child birth curred after the age of 30, there 
appeared to be no protective effect with relative risk of 0.94%. Evidence suggests that 
with child birth over age of 35 have increased risk of breast cancer. In my study most 
breast cancer occurred in multipara and is about 72%.  Incidence in nullipara is 8%. 
10% of cases were grand multipara.
 
Lactational status
Though  42%  of  our  patients  have  lactated  for  more  than  one  year,  lactation 
doesn’t seem to have any protective effect.
Clinical featurexxvii
Majority of our women in my study presenting with Carcinoma Breast had lump 
in the breast. Pain in the breast in 15 cases and 4 cases had nipple discharge.
Most common occurrence of breast cancer in our study is right side 46%. 54% of 
cases in left side. The primary site of cancer in the breast is upper outer quadrant 44%. 
12% of cases in upper inner quadrant.18% of cases in lower outer and 12% of cases in 
lower inner quadrant.10% in central and 10% diffuse.
Our  study well  correlated with the western study that  upper outer  quadrant  is 
common and lower inner quadrant 12%and lower outer quadrant 18%.
S. no Quadrant Devita My study
1 Upper outer 48% 44%
2 Upper inner 15% 12%
3 Lower outer 11% 18%
4 Lower inner 6% 12%
5 Central 17% 10%
6 Diffuse 3% 4%
Pathological featuresxxviii
Histological assessment helps to know the patient prognosis and allows greater 
understanding of biology of the disease. Several pathological classifications are in use. 
The most commonly used are presented by WHO. It is proved that most tumors arise in 
the terminal duct of breast regardless of pathological type.
Pathological classification of breast cancer
Most  of  the  breast  cancers  are  ductal  carcinoma  of  breast.  Others  are  less 
common.
Clinical staging
In my study only 32% of cases were early cancer. All other cases were locally 
advanced  Carcinoma  at the time of admission. Most of our patients had lump breast. 
About 70% had lump breast for more than 3 - 7 months. About 10% of the patients 
reported only after 1 year. The incidence of metastasis is about 2%. Recurrent cancer 
occurred in 1 case.
Stage No of cases
Stage I 0
Stage II A 4
Stage II B 20
Stage III A 19
Stage III B 5
Stage IV 1
The best indicators of the prognosis are tumor size and lymph node status. In our 
study clinically palpable nodes in axilla and Supraclavicular region were 74%. Among 
them histologically positive were only in 62% cases.
The  second  major  site  of  regional  metastasis  for  cancer  breast  is  internal 
mammary nodes. Because of the non availability of the sophisticated investigation we 
have not evaluated its incidence.
Our  study  of  nodal  status  was  mainly  on  axillary  nodal  involvement. 
Approximately 74% have evidence of spread to axillary lymph node. But in study it was 
62%. The likelihood of axillary node involvement appears to be directly related to the 
size of primary tumor. Detection of axillary involvement by physical examination has 
high false positive and false negative rate.
If  the  axillary  nodes  are  palpable  histological  evidence  of  metastasis  was  not 
found in 12%. Conversely if axillary node were not detectable clinically, metastasis was 
detected in 15% of cases histologically. The short coming of the clinical examination is 
of particular importance. Because, histological involvement of axillary node has high 
correlation with the prognosis. In our study the false positivity rate was 12%.
Supraclavicular node and internal mammary node involvement is associated with 
poor prognosis.
No site is immune to the spread of tumor most commonly involved organs are 
bone, lungs, brain, skin, liver, Ovary and peritoneum.
Diagnosis of Carcinoma Breast
Confirmation of the clinical diagnosis is mainly by pathology
FNACxxix
It has an advantage of being performed as an outpatient procedure and immediate 
results are obtained. The technique we followed is,  by using 23G needle, atraumatic 
aspiration after fixing the mass, by 3 or more pass.10 ml syringe is used to aspirate the 
material and it is spread on a slide and sent for histopathological examination.
Out of 50 cases we submitted, the result showed that false negative rate was 2%. 
Total negative cases were 5. These 5 cases submitted for trucut biopsy and 4 cases found 
to be positive and 1 cases true negative. So ended up in a false negative rate of 2%. 
Sensitivity in our study is 90%. In our study, we have not come across false positive 
result compared to 2% as expressed in oxford text book of surgery. The disadvantage of 
aspiration  cytology  is  it  cannot  differentiate  the  insitu  carcinoma  from  invasive 
carcinoma.
Evaluation of the patients with Carcinoma Breast
Once the diagnosis of the breast cancer is made out other investigations were done 
to evaluate the patient further. All our patients were subjected to investigations like chest 
X ray, hemoglobin, complete blood count, serum alkaline phosphatase. Because of the 
non availability of the mammography, bone scan and brain scan, our patients were not 
subjected to these investigations. Our patients were routinely submitted for ultrasound 
abdomen and pelvis for liver and ovarian metastasis. 
Staging
Though there are many methods of staging, we have followed TNM staging in all 
our patients. Our study shows early Carcinoma Breast in 32% of cases.
Stage No of cases
Stage I 0
Stage II A 4
Stage II B 20
Stage III A 19
Stage III B 5
Stage IV 1
Treatment of the Carcinoma Breast xxx
The treatment of  Carcinoma Breast has changed dramatically over the past 10 
years. The disease free survival rate has not been altered much between modified radical 
mastectomy  and  other  limited  procedure  followed  by  radiotherapy.  However,  the 
ultimate  choice  of  therapy  is  influenced  by  the  personal  values  and  fears  of  the 
individual patient and final choice is that of patient herself.
Since the protocol in our institution is modified radical mastectomy and bilateral 
oopherectomy for pre menopausal early operable breast cancer, we did the same for 9 
cases.  Two  cases  underwent  lumpectomy  alone.  35  post  menopausal  women  were 
subjected to modified radical mastectomy. 4 cases were found to be inoperable and they 
under went palliative mastectomy. Completion mastectomy had been done for recurrent 
cases. All the cases were subjected to post operative chemotherapy and radiotherapy and 
endocrine manipulation.
Ovarian ablation overwhelmingly improved both the recurrence free survival and 
overall survival in young women but had little effect on the women more than 50 years.
Hormone therapy
Adjuvant hormonal manipulation for the treatment of the breast cancer has been 
simplified by tamoxifen.  Tamoxifen is weak estrogen agonist and moderate estrogen 
antagonist. Adjuvant Tamoxifen therapy improved both the recurrence free survival and 
overall survival. It significantly reduces the incidence of contra lateral breast disease. 
Response rate are 30% in unselected patients, 50% in ER positive patients, 70-80% in 
both ER and PR positive patients. Regular follow up to asses the endometrial thickness 
is  necessary  if  the  patient  is  on tamoxifen.  We didn’t  come across  any endometrial 
carcinoma in patients on tamoxifen. 
We  have  not  subjected  the  patients  to  adrenalectomy,  LHRH  agonist, 
aminoglutethimide, megestrol acetate for hormonal manipulation.
Chemotherapy
As most of the patients were presented with advanced breast cancer we have tried 
combination  of  palliative  surgery,  radiotherapy,  chemotherapy  and  hormonal 
manipulation.  Our  patient  had  no  chance  to  undergo  immunotherapy  like  BCG and 
levamisole. As multi pronged approach is superior to a single agent, we have given CMF 
or CAF as chemotherapy for 6 cycles. Since we had followed up the cases for only 2-3 
years  five  year  survival  rate  was  not  evaluated.  Among  the  45  patients  who  had 
chemotherapy 10 cases received CAF regime all others were on CMF regime.
Radiotherapy
All our patients had postoperative radiotherapy.
Morbidity in surgery
Three patients had post operative infection. Flap necrosis occurred in 5 cases. 15 
patients had lymph collection which was managed by needle aspiration. Lympodema is 
seen in 8 cases. 
CONCLUSION
Fifty cases of Carcinoma Breast patients were studied and the following conclusions 
are arrived 
1. Social status 
It is common in poor socio economic group.
2. Incidence
The highest incidence rate is 66 % between 30-50 years age group. They 
were affected in their prime age of life. So mass screening program is essential to 
detect early breast cancer in our society.
3. Age 
Youngest affected female is 24 years.
4. Hereditary 
There is no clear evidence about the role of heredity in carcinoma breast in 
our society
5. Menarche
88 % of our cases attained menarche between 13-15 years.
6. Parity
The predominant group affected in our study is multipara-72%. Nullipara 
is least affected group. So multipara women are not considered to be the protective 
group against carcinoma breast in this study.
7. Age of first child birth
2% cases  had  their  first  child  before  the  age  of  16.  74% of  cases  had 
between 16-23 years. Early child birth doesn’t seem to be protective in females of 
this study.
8. Breast feeding 
All patient lactate their children. 42% lactated for more than one year. Long 
period of breast feeding doesn’t seem to have any protective effect.
9. Frequency of occurrence of breast cancer is more in upper outer quadrant.
10. Left breast is most affected than Right Breast.
11. Trucut biopsy was the chief investigation of choice with 100 % true 
positivity
12. Modified radical mastectomy with or without oopherectomy is the   commonest 
surgery performed.
13.  96 % of the cases had infiltrating ductal carcinoma.
14. Only 16 cases had early breast cancer.
15.Only 90% had chemotherapy. Remaining 10% did not turn up for chemotherapy.
16.Axillary clearance helps in loco regional control rather than disease free survival.
17.Surgical oopherectomy is better in controlling the disease in pre menopausal women. 
Since ER and PR status could not be available in our hospital in the present setup.
The prognosis depends upon the tumor differentiation, TNM staging, axillary node 
involvement and behavior of the tumor . The best indicators of likely prognosis 
in Carcinoma Breast  are still  tumor size  and lymph node status.  However,  it  is 
realized that some large tumours will  remain confined to the breast for decades 
whereas some very small tumors are incurable at diagnosis. Hence the prognosis of 
a cancer depends not on its chronological age but on its invasive and metastatic 
potential. In an attempt to define which tumours will behave aggressively, and thus 
require early systemic treatment, a host of prognostic factors has been described. 
These include histological grade of the tumour, hormone receptor status
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